Aspire Biopharma’s Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned ...

Aspire Announces Acquisition of PolicyOne to Accelerate Innovation and Strengthen Technology Platform

Aspire announced it has acquired PolicyOne from One Inc., a strategic move designed to strengthen Aspire’s ability to ...
Yahoo Finance

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight ...

H1 2026: Finalize formulation and manufacture test product. H1 2026 Initial Phase 1 pharmacokinetic clinical cross-over study. "Our pipeline is focused on research in therapeutic areas where we can ...

Aspire Biopharma’s BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Convenient Size at the Convenience Store ESTERO, FL / ACCESS Newswire / March 10, 2026 / Aspire Biopharma Holdings, ...
Yahoo Finance

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

Aspire has multiple product candidates in key areas of medical needs such as a fast-acting aspirin product for cardiology emergencies and pain management, a proprietary Viagra/Cialis combination ...

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety ...